General MedicationsORALGeneric
TEKTURNA
ALISKIREN HEMIFUMARATE
Standard Dose
EQ 37.5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview TEKTURNA is listed in Drugs@FDA under application 210709 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient ALISKIREN HEMIFUMARATE Form and strength CAPSULE, PELLET;ORAL - EQ 37.5MG BASE Sponsor NODEN PHARMA Submission history Latest submission status date: 2017-11-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview TEKTURNA is listed in Drugs@FDA under application 210709 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient ALISKIREN HEMIFUMARATE Form and strength CAPSULE, PELLET;ORAL - EQ 37.5MG BASE Sponsor NODEN PHARMA Submission history Latest submission status date: 2017-11-14 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.